☆ 4.7 Review

Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy

BIOMEDICINE & PHARMACOTHERAPY (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Regulatory cells and the effect of cancer immunotherapy

Maria Iglesias-Escudero et al.

Summary: Multiple types of regulatory cells, such as Tregs, Mregs, MDSCs, tolDCs, Bregs, and MSCs, play a role in regulating the immune response, including the anti-tumor immune response. The presence of regulatory cells in tumor tissues is linked to poor prognosis, but eliminating Tregs can also lead to harmful autoimmunity. Immune checkpoint inhibitors may function by blocking these regulatory molecules and enhancing the immune response. This review aims to gather current knowledge on the effects of immunotherapy on regulatory cells and their potential benefits in response to treatment.

MOLECULAR CANCER (2023)

Add to Collection

Article Acoustics

Non-invasive Assessment of Axillary Lymph Node Metastasis Risk in Early Invasive Breast Cancer Adopting Automated Breast Volume Scanning-Based Radiomics Nomogram: A Multicenter Study

Hui Wang et al.

Summary: The aim of this study was to develop a non-invasive tool based on radiomics and ultrasound features to evaluate axillary lymph node metastasis in patients with early invasive breast cancer. A total of 179 ABVS images were retrospectively analyzed and used to establish a radiomics nomogram model, which showed moderate predictive performance. This model can help clinicians choose diagnostic and therapeutic protocols for axillary lymph node metastasis.

ULTRASOUND IN MEDICINE AND BIOLOGY (2023)

Add to Collection

Article Oncology

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

Lixiu Peng et al.

Summary: This study assessed the efficacy of immunotherapy in Chinese patients with KRAS-mutant non-small cell lung cancer (NSCLC) using real-world data. The results showed that immunotherapy achieved longer overall survival (OS) than chemotherapy in these patients, regardless of the treatment line or mutation subtype.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies

Luis Mejias Sosa et al.

Summary: This study found that the addition of dendritic cell vaccines (DCV) to neoadjuvant chemotherapy (NAC) led to a slight increase in the proportion of CD8 cells in triple-negative breast cancer (TNBC) samples, but the increase was not statistically significant. However, a higher CD8 cell proportion was associated with pathological complete response in the vaccinated group. Overall, stimulating the antitumor immune system using DCV and NAC may be beneficial for TNBC patients.

BIOMEDICINES (2023)

Add to Collection

Article Oncology

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma

Alexander C. J. van Akkooi et al.

Summary: Survival rates for stage III melanoma are poor, but neoadjuvant immunotherapy has shown promise in improving relapse-free survival rates. Multiple phase 2 trials have demonstrated that neo-adjuvant immunotherapy induces major pathologic response rates, leading to better outcomes. Therefore, neoadjuvant immunotherapy should be considered as the best medical practice for macroscopic stage III melanoma.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Cell Biology

The tumor-immune ecosystem in shaping metastasis

Yang Gao et al.

Summary: A better understanding of the interactions between tumor cells and the host immune system is crucial for developing new therapies and reducing mortality in cancer metastasis. These interactions involve the recruitment of immune cells by tumor cells, which in turn promote various steps of metastasis. Additionally, the tumor-host immunological interactions create a premetastatic niche in distant organs that facilitates metastasis. This review summarizes recent findings on how tumor cells and immune cells regulate each other to promote the formation of metastases at major organ sites.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2023)

Add to Collection

Review Oncology

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives

Carmine Valenza et al.

Summary: Immune checkpoint inhibitors have had a significant impact on the treatment of breast cancer, especially in the case of triple-negative breast cancer. Current research aims to improve upon these results by exploring novel combinations and strategies, investigating the role of ICIs beyond TNBC, and better selecting patients for treatment. This narrative review provides a summary of the evolving landscape of immunotherapeutic treatments for breast cancer, highlighting current challenges and future perspectives.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

Lanxiang Huang et al.

Summary: By loading immunogenic cell death inducers into breast cancer-derived exosomes, a DC vaccine called HELA-Exos was created. HELA-Exos exhibited high efficacy in inducing immune cell death in breast cancer cells and activating immune responses that suppressed tumor growth.

MOLECULAR CANCER (2022)

Add to Collection

Review Oncology

Research progress on dendritic cell vaccines in cancer immunotherapy

Jifeng Yu et al.

Summary: DC vaccines have shown promising results in the treatment of hematological malignancies, including AML and MDS. Different strategies have been explored, such as using mo-DCs and DCleu as the main types of DCs, and loading DCs with various cancer-related molecules to enhance efficacy. Additionally, combination with conventional chemotherapy, specific antibodies, and immune checkpoint-targeting therapies have been investigated to improve the outcomes of DC vaccination. Overall, significant progress has been made in the field of DC vaccine immunotherapy.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Oncology

Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Mingzhi Zhang et al.

Summary: This study investigated the safety and efficacy of autologous CD7-chimeric antigen receptor (CAR) T cells in patients with relapsed and refractory T-ALL/LBL and found promising and durable antitumor response in these patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade

Xuewei Bai et al.

Summary: The study found that Aspartate beta-hydroxylase (ASPH) can upregulate the expression of PD-L1 on breast and liver tumor cells through the ASPH-MYC signaling cascade, leading to immune evasion. The combination of a lambda phage vaccine targeting ASPH and PD-1 inhibitors can effectively inhibit the growth and progression of TNBC and HCC, significantly improving the therapeutic effect.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects

Shuquan Zhang et al.

Summary: A novel tumor vaccine containing MUC1 antigen and two adjuvants was developed by the research group, which effectively and safely prevented and treated tumors expressing MUC1 antigen by enhancing specific humoral and cellular immune responses.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Engineering, Biomedical

Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune microenvironment

Wendi Huo et al.

Summary: This study reported a strategy to achieve effective immunotherapy of TNBC by improving immunogenicity and reversing suppressive tumor microenvironment. A CaCO3 biomineralized hydrogel DC vaccine was synthesized to increase immunogenicity and to enhance the pH of TME, thereby reversing immune inhibitory effects.

BIOMATERIALS (2022)

Add to Collection

Review Immunology

Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

Chunmei Fu et al.

Summary: Dendritic cells (DCs) are potent antigen presenting cells that play a critical role in activating immune responses. Despite the limited success of current DC-based cancer vaccines, recent studies have highlighted the important role of type 1 conventional DCs in activating tumor-specific CD8 T cells. Further research and refinement are needed to fully realize the potential of DC-based cancer vaccines.

IMMUNOLOGICAL INVESTIGATIONS (2022)

Add to Collection

Article Oncology

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

Brendan D. Curti et al.

Summary: The combination of V937 and ipilimumab has shown promising antitumor activity in patients with advanced melanoma, including those who have had disease progression on previous anti-PD-1 therapy. The toxicities associated with this combination therapy are manageable and consistent with those seen with the individual monotherapies.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Xiao Han et al.

Summary: This study investigates the predictive role of ctDNA short-term dynamic change in advanced NSCLC patients treated with sintilimab plus docetaxel, and finds that ctDNA clearance at 6th week is associated with shorter progression-free survival.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Immunology

Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer

Josue Odales et al.

Summary: This study developed an innovative Variable Epitope Library (VEL) vaccine platform for the research of MUC1 antigen in cancer immunotherapy. The results showed that vaccination with 23L VEL immunogens, containing the entire signal peptide region of MUC1, reduced tumor area, while vaccination with 9MUC1spL, a CD8(+) T cell epitope-based VEL derived from MUC1 signal peptide, showed similar tumor area reduction but a decrease in lung metastasis. In addition, vaccination induced a large pool of CD8(+) T cells recognizing variant epitopes from 9MUC1spL. Furthermore, MUC1 variable number tandem repeat (VNTR)-based VELs reduced metastatic burden when dendritic cells and M13 recombinant bacteriophages were used as vaccine carriers.

VACCINE (2022)

Add to Collection

Article Oncology

Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial

Hee Kyung Ahn et al.

Summary: This study aimed to investigate the feasibility and efficacy of neoadjuvant treatment with atezolizumab, docetaxel, trastuzumab, and pertuzumab in patients with ERBB2-positive early breast cancer. The results showed that this treatment regimen had an acceptable pCR rate and modest toxic effects, highlighting the importance of further research on the use of this combination in early breast cancer.

JAMA ONCOLOGY (2022)

Add to Collection

Article Cell Biology

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

Giorgio Ottaviano et al.

Summary: This study demonstrates the feasibility, safety, and therapeutic potential of CRISPR-engineered immunotherapy. By using genome editing techniques, allogeneic T cells were modified to provide off-the-shelf alternatives to autologous CAR T cell therapies, showing promising results in the treatment of B-ALL.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Oncology

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

Adrienne G. Waks et al.

Summary: This study investigated the safety and tolerability of T-DM1 in combination with pembrolizumab for HER2-positive metastatic breast cancer. The results showed that this regimen was safe and well-tolerated, but further research is needed to determine the role of checkpoint inhibition in the management of HER2-positive metastatic breast cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Medicine, General & Internal

Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy

Yan Yan et al.

Summary: Esophageal cancer, with high incidence and poor prognosis, has two major histological types: squamous cell carcinoma and adenocarcinoma, which differ in their epidemiology and treatment options. Immunotherapy, particularly adjuvant immune checkpoint inhibitors (ICIs), has emerged as a potential treatment for resectable esophageal cancer. Recent clinical trials have shown promising results with ICIs for resectable esophageal cancer, although some concerns remain.

CHINESE MEDICAL JOURNAL (2022)

Add to Collection

Article Immunology

acquisition cytometry Modelos Biologicos (Instituto de Investiga- animal care.

Josue Odales et al.

Summary: This study utilized an innovative Variable Epitope Library vaccine platform to develop MUC1 signal peptide- and VNTR-derived immunogens, demonstrating their immunogenic and antitumor properties.

VACCINE (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Dendritic cell vaccine therapy for colorectal cancer

Amanda L. Wooster et al.

Summary: Current standard-of-care interventions for colorectal cancer include surgical resection, chemotherapy, and targeted therapies, with the combination of anti-vascular endothelial growth factor agents and chemotherapy being an important development. Dendritic cell vaccines targeting tumor-derived blood vessels may disrupt tumor angiogenesis and decrease tumor growth, but clinical results have historically been disappointing. The success of Sipuleucel-T in prostate cancer patients has revived the clinical development of dendritic cell vaccines for other types of cancer, including colorectal cancer.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Article Immunology

Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer

Mahdi Dehghan-Manshadi et al.

Summary: The study showed that DCs- and PBMCs-based vaccines pulsed with designed peptides significantly increased IFN-γ and granzyme B levels in T cells, leading to a stronger immune protective response. Mice vaccinated with F4d and F4e subgroups displayed significantly smaller tumor sizes and prolonged survival time after challenging with 4T1 cells, indicating the effectiveness of the PBMCs pulsed F4 peptide-based vaccine.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

Hoyoung M. Maeng et al.

Summary: The study investigated a dendritic cell vaccine targeting HER2 in patients with metastatic cancer or high-risk bladder cancer, showing evidence of immunogenicity and preliminary clinical benefit in patients.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells

Angelique Sao-Mai Sy Tay et al.

Summary: This study demonstrates that targeting CD133 in a MHC-independent manner is an effective strategy against cancer stem cells in triple-negative breast cancer, leading to tumor growth inhibition in a syngeneic mouse model of TNBC.

MOLECULAR THERAPY-ONCOLYTICS (2021)

Add to Collection

Article Immunology

Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial

David A. Bernal-Estevez et al.

Summary: This study investigates the safety and immunogenicity of autologous antigen-free DCs administered to breast cancer patients (BCPs) in combination with NAC-AC. The results suggest that the administration of DCs in combination with NAC-AC enhances the functional capacity of T cells in BCPs, potentially potentiating the adjuvant effect of ICD induced by NAC-AC on T cells and increasing the immunogenicity of tumors as cryptic vaccines.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

Marta Santisteban et al.

Summary: The study demonstrated that adding DCV to NAC in breast cancer patients is safe and can increase pathological complete response rate, especially benefiting PD-L1-negative tumors. DCV modify the tumor environment and induce cellular and humoral responses in peripheral blood without impacting outcomes.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)

Christian F. Singer et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Pharmacology & Pharmacy

Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach

Belen P. Solans et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

MUC1 in Cancer Immunotherapy - New Hope or Phantom Menace?

M. S. Syrkina et al.

BIOCHEMISTRY-MOSCOW (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Neoantigen vaccine: an emerging tumor immunotherapy

Miao Peng et al.

MOLECULAR CANCER (2019)

Add to Collection

Article Immunology

Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response

Krithika N. Kodumudi et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Review Oncology

CD133 in Breast Cancer Cells: More than a Stem Cell Marker

Federica Brugnoli et al.

JOURNAL OF ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Engineering dendritic cell vaccines to improve cancer immunotherapy

Caleb R. Perez et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

Lina Liu et al.

MOLECULAR THERAPY (2018)

Add to Collection

Review Cell Biology

Dendritic cell-based immunotherapy

Rachel L. Sabado et al.

CELL RESEARCH (2017)

Add to Collection

Article Oncology

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial

Lea Lowenfeld et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer

Lea Lowenfeld et al.

ONCOIMMUNOLOGY (2017)

Add to Collection

Article Immunology

Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth

Paul D. Bryson et al.

VACCINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Human breast cancer-derived soluble factors facilitate CCL19-induced chemotaxis of human dendritic cells

Hyundoo Hwang et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Oncology

Runx2 Is a Novel Regulator of Mammary Epithelial Cell Fate in Development and Breast Cancer

Thomas W. Owens et al.

CANCER RESEARCH (2014)

Add to Collection

Article Pharmacology & Pharmacy

Dendritic Cell Vaccine and Cancer Treatment: New Patents

Andre A. R. Aleixo et al.

RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2014)

Add to Collection

Review Immunology

Decisions About Dendritic Cells: Past, Present, and Future

Ralph M. Steinman

ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)

Add to Collection

Review Cell Biology

The road to the discovery of dendritic cells, a tribute to Ralph Steinman

Donald A. Rowley et al.

CELLULAR IMMUNOLOGY (2012)

Add to Collection

Review Oncology

Cancer immunotherapy via dendritic cells

Karolina Palucka et al.

NATURE REVIEWS CANCER (2012)

Add to Collection

Article Biochemical Research Methods

A COMBINATION OF EXOSOMES CARRYING TSA DERIVED FROM HLA-A2-POSITIVE HUMAN WHITE BUFFY COAT AND POLYI:C FOR USE AS A SUBCELLULAR ANTITUMOR VACCINATION

Wei-na Ren et al.

JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY (2011)

Add to Collection

Article Hematology

Runx2 in normal tissues and cancer cells: A developing story

Karen Blyth et al.

BLOOD CELLS MOLECULES AND DISEASES (2010)

Add to Collection

Article Immunology

MUC1 immunotherapy

Richard E. Beatson et al.

IMMUNOTHERAPY (2010)

Add to Collection

Review Immunology

Directing dendritic cell immunotherapy towards successful cancer treatment

Rachel Lubong Sabado et al.

IMMUNOTHERAPY (2010)

Add to Collection

Review Multidisciplinary Sciences

Taking dendritic cells into medicine

Ralph M. Steinman et al.

NATURE (2007)

Add to Collection

Article Oncology

The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer

Inka Seil et al.

INTERNATIONAL JOURNAL OF CANCER (2007)

Add to Collection

Article Multidisciplinary Sciences

Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells

Hai Qi et al.

SCIENCE (2006)

Add to Collection

Article Cell Biology

Human epidermal Langerhans cells differ from monocyte-derived Langerhans cells in CD80 expression and in secretion of IL-12 after CD40 cross-linking

M Peiser et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2004)

Add to Collection

Article Oncology

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A phase 1 study

JC Oosterwijk-Wakka et al.

JOURNAL OF IMMUNOTHERAPY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.